Peters HA - Search Results

1

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG. Foekens JA, et al. Among authors: peters ha. J Natl Cancer Inst. 1995 May 17;87(10):751-6. doi: 10.1093/jnci/87.10.751. J Natl Cancer Inst. 1995. PMID: 7563153

2

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA. Meijer-van Gelder ME, et al. Among authors: peters ha. Cancer Res. 2004 Jul 1;64(13):4563-8. doi: 10.1158/0008-5472.CAN-03-3848. Cancer Res. 2004. PMID: 15231667

3

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA. Berns EM, et al. Clin Cancer Res. 2003 Apr;9(4):1253-8. Clin Cancer Res. 2003. PMID: 12684392

4

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: peters ha. Cancer Res. 1992 Nov 1;52(21):6101-5. Cancer Res. 1992. PMID: 1394237

5

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG. Foekens JA, et al. Among authors: peters ha. Cancer Res. 1989 Nov 1;49(21):5823-8. Cancer Res. 1989. PMID: 2676151

6

Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.

Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Kramer MD. Foekens JA, et al. Among authors: peters ha. Cancer Res. 1995 Apr 1;55(7):1423-7. Cancer Res. 1995. PMID: 7882345

7

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: peters ha. J Clin Oncol. 1994 Aug;12(8):1648-58. doi: 10.1200/JCO.1994.12.8.1648. J Clin Oncol. 1994. PMID: 8040677

8

Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.

Foekens JA, Sieuwerts AM, Stuurman-Smeets EM, Peters HA, Klijn JG. Foekens JA, et al. Among authors: peters ha. Br J Cancer. 1993 Feb;67(2):232-6. doi: 10.1038/bjc.1993.45. Br J Cancer. 1993. PMID: 8431356 Free PMC article.

9

Prognostic significance of cathepsins B and L in primary human breast cancer.

Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. Foekens JA, et al. Among authors: peters ha. J Clin Oncol. 1998 Mar;16(3):1013-21. doi: 10.1200/JCO.1998.16.3.1013. J Clin Oncol. 1998. PMID: 9508185

10

Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.

Sieuwerts AM, Klijn JG, Henzen-Logmand SC, Bouwman I, Van Roozendaal KE, Peters HA, Setyono-Han B, Foekens JA. Sieuwerts AM, et al. Among authors: peters ha. Int J Cancer. 1998 Jun 10;76(6):829-35. doi: 10.1002/(sici)1097-0215(19980610)76:6<829::aid-ijc11>3.0.co;2-y. Int J Cancer. 1998. PMID: 9626349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters